{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:11:08Z","timestamp":1790647868152,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Huntington's chorea (HC) is commonly managed with neuroleptic medications, though there is little evidence to support their use. This study aimed to perform a real\u2010world comparison of the efficacy of risperidone and olanzapine to tetrabenazine (TBZ) for HC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Enroll\u2010HD database was used to perform a propensity score\u2010matched comparison of risperidone and olanzapine to TBZ, regarding their efficacy in controlling chorea. Participants with motor manifest Huntington's disease (HD) were grouped according to their use of risperidone, olanzapine, or TBZ. For the three groups, independent propensity score matching was performed on participants\u2019 baseline total functional score (TFC), baseline total motor score (TMS), disease burden score, CAG repeat length, baseline age, region, sex, and body mass index. Independent samples <jats:italic>t<\/jats:italic> test was used to calculate the differences between the groups in the annual rate of change of the TMS from the baseline to the second available visit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The risperidone (n\u2009=\u200972) and olanzapine groups (n\u2009=\u200977) had annualized increases (worsening) in the TMS of only 1.47 points and 3.20 points, respectively, compared to 5.70 points in the two matched TBZ groups (n\u2009=\u200972) (<jats:italic>P<\/jats:italic>\u2009=\u20090.019) and (n\u2009=\u200977) (<jats:italic>P<\/jats:italic>\u2009=\u20090.143), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In the absence of prospective data, this analysis of the Enroll\u2010HD database found that the neuroleptics risperidone and olanzapine seemed to at least be comparable to TBZ at controlling HC. These results demonstrate that neuroleptics may have comparable efficacy to TBZ for the treatment of HC. Further prospective studies are needed to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mdc3.12706","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T01:38:46Z","timestamp":1541727526000},"page":"132-138","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparing Risperidone and Olanzapine to Tetrabenazine for the Management of Chorea in Huntington Disease: An Analysis from the Enroll\u2010HD Database"],"prefix":"10.1002","volume":"6","author":[{"given":"Jordan L.","family":"Schultz","sequence":"first","affiliation":[{"name":"Department of Psychiatry The University of Iowa Hospitals and Clinics  Iowa City IA United States"},{"name":"Department of Neurology The University of Iowa Hospitals and Clinics  Iowa City IA United States"},{"name":"Department of Pharmaceutical Care The University of Iowa Hospitals and Clinics  Iowa City IA United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kamholz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry The University of Iowa Hospitals and Clinics  Iowa City IA United States"},{"name":"Department of Neurology The University of Iowa Hospitals and Clinics  Iowa City IA United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peg C.","family":"Nopoulos","sequence":"additional","affiliation":[{"name":"Department of Psychiatry The University of Iowa Hospitals and Clinics  Iowa City IA United States"},{"name":"Department of Neurology The University of Iowa Hospitals and Clinics  Iowa City IA United States"},{"name":"Stead Family Department of Pediatrics The University of Iowa Hospitals and Clinics  Iowa City IA United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Killoran","sequence":"additional","affiliation":[{"name":"Department of Neurology The University of Iowa Hospitals and Clinics  Iowa City IA United States"},{"name":"The Veteran's Affairs Medical Center  Iowa City IA United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-62"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.06.001"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/currents.RRN1260"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26014"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25500"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-012-0165-x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10401230701844802"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12388"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0670-4"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12097"},{"key":"e_1_2_8_16_1","unstructured":"Assistance Publique \u2013 Hopitaux de Paris.Neuroleptic and Huntington disease comparison of: olanzapine tetrabenazine and tiapride (NEUROHD). Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00632645. Accessed July 30 2018."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085430"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2003.10.007"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.017822"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25007"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318166da60"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-62"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2016.05.002"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005817"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000104913.75206.62"},{"key":"e_1_2_8_26_1","unstructured":"NDA 21\u2010894 Xenazine\u00ae (tetrabenazine) Risk evaluation and mitigation strategy. Food and Drug Administration. 2012.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021894s001s002REMS.pdf. Accessed 3\/2\/2018"},{"key":"e_1_2_8_27_1","volume-title":"Austedo (deutetrabenazine) [package insert]","year":"2017"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8233-x"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmdc3.12706","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.12706","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.12706","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.12706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:16:15Z","timestamp":1760958975000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.12706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1002\/mdc3.12706"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.12706","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]},"assertion":[{"value":"2018-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}